英诺特：9月15日召开董事会会议

Group 1 - The core point of the article is that Innotec (SH 688253) announced a board meeting to discuss the first grant of restricted stock under the 2025 incentive plan, indicating ongoing corporate governance and strategic planning [1] - Innotec's revenue for the year 2024 is entirely derived from the in vitro diagnostics industry, highlighting its focused business model [1] - As of the report, Innotec has a market capitalization of 4.2 billion yuan, reflecting its valuation in the market [1] Group 2 - A significant breakthrough in a new drug from China has been recognized by both Chinese and U.S. officials for its breakthrough efficacy, generating excitement at the World Lung Cancer Conference [1]